Tag Archives: Mark Breidenbach

Oppenheimer Reaffirms Their Buy Rating on Synlogic Inc (SYBX)

Oppenheimer analyst Mark Breidenbach maintained a Buy rating on Synlogic Inc (SYBX – Research Report) today and set a price target of $15. The company’s shares closed yesterday at $8.26. Breidenbach commented: “Synlogic reported 1Q19 earnings on 5/9 and reviewed

Oppenheimer Believes VolitionRX (NYSE MKT: VNRX) Still Has Room to Grow

In a report released yesterday, Mark Breidenbach from Oppenheimer maintained a Buy rating on VolitionRX (VNRX – Research Report), with a price target of $5. The company’s shares closed yesterday at $3.28, close to its 52-week high of $3.63. Breidenbach

Oppenheimer Maintains a Buy Rating on Alpine Immune Sciences Inc (ALPN)

Oppenheimer analyst Mark Breidenbach maintained a Buy rating on Alpine Immune Sciences Inc (ALPN – Research Report) yesterday and set a price target of $13. The company’s shares closed yesterday at $6.23. Breidenbach said: “Thursday, Alpine Immune reported 1Q earnings

Analysts Are Bullish on These Healthcare Stocks: Gamida Cell Ltd (GMDA), Regeneron (REGN)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Gamida Cell Ltd (GMDA – Research Report) and Regeneron (REGN – Research Report) with bullish sentiments. Gamida Cell Ltd (GMDA) In a

Oppenheimer Sticks to Its Buy Rating for Compugen Ltd (CGEN)

In a report released yesterday, Mark Breidenbach from Oppenheimer maintained a Buy rating on Compugen Ltd (CGEN – Research Report), with a price target of $9. The company’s shares closed yesterday at $3.68. Breidenbach commented: “Monday, we sat in on

Oppenheimer Keeps a Buy Rating on VolitionRX (VNRX)

In a report released today, Mark Breidenbach from Oppenheimer maintained a Buy rating on VolitionRX (VNRX – Research Report), with a price target of $5. The company’s shares closed yesterday at $3.16, close to its 52-week high of $3.45. Breidenbach